DNA pooling-based genome-wide screen for genetic determinants of response to antiplatelet therapy after PCI and validation

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCH-11001198

Enrollment

Unknown

Registered

2011-03-08

Start date

2011-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

Total:Clopidogrel, interacting drugs, genetic variation, plasma biomarker

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Coronary artery disease patients who undergo primary percutaneous coronary intervention and clopidogrel treatment

Exclusion criteria

Exclusion criteria: 1. Patients who are concomitant using oral coumarin derivates or other anticoagulant treatment and with INR larger than 1.5, 10 days before operation; 2. Any contraindication to aspirin or clopidogrel therapy; 3. Patients with pre-existing bleeding disorders; 4. Known bleeding disorders; 5. Subject is pregnant or lactating or planning to become pregnant.

Design outcomes

Primary

Measure	Time frame
Major adverse cardiac events;	—

Secondary

Measure	Time frame
Bleeding events;	—

Countries

China

Contacts

Public ContactShi-Long Zhong

zhongshilong@gmail.com+86 20 83827812-51157

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026